Autoantibody diseases

At Johnson & Johnson, we are relentlessly driven to make a difference in the lives of patients and families impacted by immune-mediated diseases. This commitment includes autoantibody diseases, which are caused by harmful antibodies – also known as autoantibodies – made by one’s own body that attack critical organs and tissues.

Our research has the potential to help the estimated 240 million people worldwide who suffer from autoantibody diseases, many of which have no safe, effective treatments. Johnson & Johnson aims to revolutionize care for patients with a novel therapy that reduces autoantibodies while maintaining immune function, furthering our goal to redefine treatments for immune diseases.

Learn more about autoantibody diseases, which comprise a large and varied group of more than 80 chronic autoimmune and acute alloimmune conditions, that span rare and prevalent diseases including: